Bullish Momentum: Aspire Biopharma (NASDAQ: ASBP) Lights Up 14 Technical Indicators On Early Move

*Sponsored Market Crux Announces Its Next Potential Breakout Idea For Wednesday Morning—(4/9/2025). Take A Look At Aspire Biopharma (NASDAQ: ASBP) While It’s Still Early! Here’s What We Can Tell You So Far… RSI Levels Below 30 Suggest Aspire Biopharma (NASDAQ: ASBP) May Be  Entering Oversold Territory—Suggesting The Potential For Trend Reversal. A Patented Sublingual System Is Targeting A $100B Market With Faster And  More Efficient Delivery. Aspire Biopharma (NASDAQ: ASBP) Is Newly Listed On Nasdaq And Still  Flying Under The Radar. A Sublingual Aspirin Formulation Aims To Reach Therapeutic Levels  In Under Two Minutes. The Company Is Advancing A Fast-Acting Aspirin As Part Of The  Expanding Pain Relief Segment. Manufacturing Support Is In Place With Glatt And Discussions  Underway With ThermoFisher. A Phase 1 Clinical Trial For Sublingual Aspirin Is Expected To  Begin In April 2025. See Why Aspire Biopharma (NASDAQ: ASBP) is Topping Our Early  Watchlist Right Now… April 9, 2025 Dear Reader, Please tell me you’re watching Aspire Biopharma (NASDAQ: ASBP) right now. (ASBP) is triggering 14 bullish signals, including the “momentum indicator” on TradingView’s dashboard using the 1 minute time-frame. It’s official—Aspire Biopharma (NASDAQ: ASBP) just flipped the switch on its Phase 1 clinical trial.  With a goal of testing the absorption speed and safety of its high-dose, orally absorbed aspirin, the company is activating sites, enrolling participants, and already targeting a Q2 readout.  For a profile still under the radar, this kind of progress could shift attention fast. There’s about 15 minutes to go before the bell rings. (ASBP) reached $.47 in the early session, moving approximately 14% from yesterday’s $.4122 open.  Have you taken a look at Aspire Biopharma (NASDAQ: ASBP) yet?  After Friday’s profile showcased an approximate 18% early move, we’re back with another breakout idea—still under $1 and advancing in a $100B+ sector. This time, it’s a biopharma innovator developing a breakthrough delivery system that could transform how life-saving treatments are absorbed—delivering therapeutic effects in under two minutes. Early results are impressive.  The tech is patented, fast-acting, and already in development for commercialization.  Yet, the company remains largely under the radar… for now.  Keep reading to see why Aspire Biopharma (NASDAQ: ASBP) is topping our watchlist heading into today—Wednesday, April 9, 2025. Just recently listed on the Nasdaq in February of this year, Aspire Biopharma (NASDAQ: ASBP) is a little-known company in the pharmaceutical technology space with a patent-protected sublingual absorption system designed to deliver treatments faster, more efficiently, and with fewer side effects than traditional methods. With multiple product launches expected this year, major licensing deals in the works, and an experienced leadership team guiding its expansion, Aspire Biopharma (NASDAQ: ASBP) is positioning itself as a key player in the next generation of treatment delivery. And with its RSI levels dipping below 30, Aspire Biopharma (NASDAQ: ASBP) appears to be heading towards “oversold territory” and potentially paving the way for a quick trend reversal.  Aspire Biopharma (NASDAQ: ASBP): Transforming Treatment Delivery with Sublingual Innovation Aspire Biopharma (NASDAQ: ASBP) has developed a patent-protected, proprietary system that enables rapid absorption of treatments through sublingual delivery—allowing them to enter the bloodstream without needing to pass through the digestive system or liver first. Faster absorption: Treatments reach therapeutic levels in under two minutes instead of 20+ minutes. Lower dosages, fewer side effects: Bypassing the liver reduces strain and improves efficacy at smaller doses. More accessible: Can be administered even to those who have difficulty swallowing pills or are unconscious. This unique system is applicable to a wide range of existing treatments—making it a highly versatile platform with significant market potential. Aspire Biopharma (NASDAQ: ASBP)’s Flagship Product: A Life-Saving Therapy with Game-Changing Potential Aspire Biopharma (NASDAQ: ASBP)'s lead development is a sublingual aspirin formulation designed for rapid emergency response in cardiovascular events. Heart attacks and strokes remain a leading cause of emergency hospital visits worldwide—and in these situations, every second counts. Traditional aspirin can take 20+ minutes to reach peak absorption—Aspire’s sublingual formulation has been shown in initial studies to achieve therapeutic levels in less than two minutes. No GI side effects: Unlike standard aspirin, Aspire’s formulation is pH neutral, reducing the risk of stomach irritation and long-term gastrointestinal damage. Aspire is actively pursuing an FDA Fast Track 505(b)(2) approval—a pathway designed to accelerate the approval process for treatments that improve upon already-established therapies. FDA Fast Track: A Potential Catalyst for Aspire Biopharma (NASDAQ: ASBP) The FDA Fast Track designation was established under the FDA Modernization Act of 1997 to accelerate the development and review of treatments addressing serious conditions and unmet medical needs.  Aspire Biopharma (NASDAQ: ASBP) is actively pursuing this designation for its sublingual aspirin formulation, which has demonstrated the potential for rapid absorption in emergency cardiovascular events. If granted, Fast Track status could be a major catalyst, unlocking: Expedited regulatory review to shorten approval timelines. Early and rolling FDA submissions, allowing Aspire Biopharma (NASDAQ: ASBP) to submit data as it becomes available instead of waiting for a full package. More frequent engagement with the FDA, ensuring a smoother development path with potential mid-process adjustments. By securing Fast Track designation, Aspire Biopharma (NASDAQ: ASBP) could be positioned ahead of competitors, accelerating its route to commercialization while making a meaningful impact in critical care treatment. As part of this process, Aspire Biopharma (NASDAQ: ASBP) is preparing for a Phase 1 clinical trial set to begin in April 2025, marking a key milestone on its path toward regulatory approval.  Aspire Biopharma (NASDAQ: ASBP) Targets a Potential $125B  Pain Management Market Pain management remains one of the largest and most competitive segments in healthcare, with the global analgesics market anticipated to reach $87B in 2025 and projected to reach $125B by 2034. While widely used, traditional pain relievers—including aspirin, ibuprofen, acetaminophen, and opi-oi-ds—come with significant drawbacks, including delayed absorption times, gastrointestinal irritation, and risks of overuse.  Aspire Biopharma (NASDAQ: ASBP) is aiming to solve these challenges with its sublingual absorption technology: Faster Relief: Traditional aspirin can take 20+ minutes to reach effective levels in the bloodstream, while Aspire Biopharma (NASDAQ: ASBP)’s sublingual aspirin has demonstrated absorption in under two minutes in early testing. Bypassing the GI Tract: Unlike oral pain relievers, Aspire Biopharma (NASDAQ: ASBP)’s sublingual aspirin avoids stomach irritation and first-pass metabolism, ensuring that more of the active ingredient reaches the bloodstream quickly. Potential Alternative in Certain Cases: With concerns around opi-oi-d-based pain treatments, Aspire's faster-acting, non-opi-oi-d pain relief option could offer an effective alternative for certain patients. Aspire Biopharma (NASDAQ: ASBP)’s Next-Gen Absorption Technology Poised to Disrupt a Potential $29B Market Aspire Biopharma (NASDAQ: ASBP) is making a move into the high-growth pre-workout supplement industry, which is projected to see significant expansion, reaching $29B by 2033.  The company recently announced plans to launch a single-dose pre-workout supplement in 2025, utilizing its patent-pending and proprietary sublingual delivery technology. Unlike traditional pre-workout supplements that require mixing with water and waiting for effects, Aspire Biopharma (NASDAQ: ASBP)’s fast-absorbing formulation is designed to work within minutes, offering a major advantage in the performance supplement market. By combining science-backed performance enhancement with a next-generation delivery method, Aspire Biopharma (NASDAQ: ASBP) is positioning itself as a key innovator in this expanding market. Recent Development… Aspire Biopharma (NASDAQ: ASBP) Strengthens Intellectual Property Portfolio with Recent Patent Filings In March 2025, Aspire Biopharma announced the filing of two provisional patent applications with the U.S. Patent and Trademark Office for its novel sublingual drug delivery platform. This technology is designed to enable rapid absorption of medications directly into the bloodstream, bypassing the gastrointestinal tract, which could lead to faster therapeutic effects and reduced side effects. ​ The company's lead product candidate, a high-dose sublingual aspirin, utilizes this innovative delivery system. Aspire Biopharma is preparing to initiate a bioavailability study in healthy volunteers in April 2025, marking a significant step toward regulatory approval.  These strategic patent filings underscore Aspire Biopharma's dedication to advancing drug delivery technologies and solidifying its position in the pharmaceutical industry. 7 Reasons Why Aspire Biopharma (NASDAQ: ASBP) is Topping Our Watchlist This Morning… 1. Potential Reversal: With RSI levels dipping below 30, Aspire Biopharma (NASDAQ: ASBP) appears to be entering oversold territory—often a signal that a trend reversal could be near.  2. Massive Market: A patented sublingual absorption system is targeting a $100B market, offering a faster, more efficient, and potentially safer way to deliver widely used treatments—placing Aspire Biopharma (NASDAQ: ASBP) at the forefront of this innovation. 3. Recent Nasdaq Listing: As a new and relatively unknown name on the Nasdaq as of February 20, 2025, Aspire Biopharma (NASDAQ: ASBP) is still flying under the radar—but that may not last for long. With its cutting-edge technology and expanding pipeline, this listing could be the catalyst that brings increased visibility and traction to the company. 4. Breakthrough in Emergency Treatment: A sublingual aspirin formulation designed to deliver therapeutic levels in under two minutes could be a game-changer for cardiovascular emergencies, and Aspire Biopharma (NASDAQ: ASBP) is actively advancing its development. 5. Expanding Into the $100B Analgesics Market: The global pain relief industry continues to grow, and Aspire Biopharma (NASDAQ: ASBP) is introducing a faster-acting, sublingual aspirin that bypasses the digestive tract—potentially offering a more efficient pain management solution. 6. Strategic Industry Partnerships: Contract manufacturers are being engaged for production, with Glatt Air Techniques already supporting clinical trials and ThermoFisher Scientific in discussions for additional manufacturing, as Aspire Biopharma (NASDAQ: ASBP) aims to scale its sublingual delivery system. 7. Upcoming Clinical Milestones: A Phase 1 clinical trial for sublingual aspirin is on track for April 2025, marking a significant step toward regulatory approval, with Aspire Biopharma (NASDAQ: ASBP) progressing through the testing process. Pull Up Aspire Biopharma (NASDAQ: ASBP) While It’s Still Early… Let’s be real—the biotech and pharmaceutical space moves fast, and the ones who spot breakthroughs early often have the upper hand.  Aspire Biopharma (NASDAQ: ASBP) has put itself in the mix with a first-of-its-kind sublingual absorption system, a pipeline of high-demand applications, and a regulatory fast track that could speed up approvals. It’s a newly listed company, still flying under the radar, yet it’s targeting a $100B+ market and positioning itself in pain management, emergency treatment, and high-performance supplements.  The pieces are in motion, and with clinical trials, upcoming product launches, and strategic manufacturing partnerships, this is a profile that could start getting more attention sooner rather than later. We have all eyes on (ASBP) this morning.  Pull up (ASBP) while it’s still early and be one of the first to take a look at it today.  (ASBP) is triggering 14 bullish signals, including the “momentum indicator” on TradingView’s dashboard using the 1 minute time-frame. Take a quick look at (ASBP) and watch for my next update—could be coming at any moment. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 04/08/2025 and ending on 04/09/2025 to publicly disseminate information about (ASBP:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). Neither Headline Media LLC, TD Media LLC and their member own shares of (ASBP:US). Please see important disclosure information here: https://marketcrux.com/disclosure/asbp/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice